Share
Share today's newsletter with a colleague
and get credit if they sign up for SmartBrief.
Referral Count:
0
Story being shared
Crucell licenses technology from Mucosis to develop vaccines
Crucell Holland, a subsidiary of Johnson & Johnson, will use Mucosis' Mimopath technology to develop vaccines against infectious diseases, as part of a deal for research and license options. The agreement entitles Mucosis to upfront and milestone fees.
Or we can send an email on your behalf